(Bloomberg) — Blood-testing startup Theranos Inc., under fire after reports that the company overstated the ability of its tests to accurately perform several dozen types of measurements, has flaws in the process it uses to validate its products, Food and Drug Administration inspectors found.
Heavily redacted inspection reports, posted Tuesday by the U.S. FDA, said that Theranos's "design validation did not ensure the device conforms to defined user needs and intended uses."
The name of the device was redacted. In addition, "the design was not validated under actual or simulated use conditions."
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
